Download full-text PDF |
Source |
---|
J Am Coll Cardiol
January 2025
Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland Ohio, USA.
Sci Adv
October 2024
Stockholm Resilience Centre, Stockholm University, 106 91, Stockholm, Sweden.
Circulation
September 2024
University of Colorado School of Medicine, Aurora (N.M.B., E.M.B.).
Circ Cardiovasc Interv
September 2024
Cardiovascular Research Foundation, New York (D.J.C.).
Background: Cerebral embolic protection devices (EPDs) were developed to mitigate the risk of stroke during transcatheter aortic valve replacement (TAVR), but their benefit remains unproven. In the PROTECTED-TAVR trial (Stroke Protection With Sentinel During Transcatheter), EPD use did not reduce periprocedural stroke (primary study outcome) but led to a 62% reduction in the secondary end point of disabling stroke. Given these results, the impact of EPDs during TAVR remains unclear.
View Article and Find Full Text PDFCirc Cardiovasc Interv
September 2024
Cardiovascular Research Foundation, New York, NY (D.J.C.).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!